Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316482 | 0.84 | CYP19A1 (0.38) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL10000116 | 0.81 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL1638482 | 0.70 | CYP19A1 (0.46) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL700313 | 0.69 | ADRA2A (0.49) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3055369 | 0.68 | CYP19A1 (0.44) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3065262 | 0.67 | SLC6A2 (0.59) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL1639415 | 0.67 | CYP19A1 (0.55) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3060612 | 0.66 | SLC6A2 (0.46) | CYP19A1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3066082 | 0.66 | SLC6A2 (0.62) | CPA1HRH3 | |
| SCHEMBL1639638 | 0.66 | IDO1 (0.47) | CYP19A1ADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124774-B2 | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124774-B2 | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100197729-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | ALLERDAN, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197729-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | ALLERDAN, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197729-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | GOT2, COQ8A, OAT | CYP19A1 2987/4885ADRA2A 905/4885ADRA2B 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.